Limited coverage drugs – aprepitant
Last updated on October 7, 2022
|
Generic name |
aprepitant |
|---|---|
| Strength | 80 mg, 125 mg, Tri-Pack 125MG-80MG CAP DS PK |
| Form |
capsule |
|
Special Authority criteria |
Approval period |
|---|---|
| For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy in combination with a 5-HT3 antagonist and dexamethasone. |
Up to a maximum number of standard, planned treatment cycles of highly-emetogenic cancer chemotherapy (usually 6 or fewer treatment cycles), as specified in the relevant BC Cancer Agency chemotherapy protocol. |
Practitioner exemptions
- Oncologists and BC Cancer-designated oncology specialists are invited to apply for individual specialist exemption from completing SA forms. See Collaborative Prescribing Agreement (PDF, 49.3KB)
Special notes
- Highly-emetogenic chemotherapy is defined by greater than 90% of patients experiencing emesis if not treated. Emetogenicity of chemotherapy is determined in accordance with the BC Cancer Agency protocols for combination chemotherapy (see individual protocols for assessment of emetogenicity and SCNAUSEA supportive care protocol rating)
- Coverage is not intended for the prevention of nausea and vomiting with cancer chemotherapy of high-moderate, low-moderate, low or rare emetogenicity. However, exceptional case coverage requests may be submitted to PharmaCare. Exceptional case submissions are required for all patients who do not meet the above Limited Coverage criteria, from all physicians (including those with specialist exemption)